Literature DB >> 358014

Effect of valproic acid on hepatic function.

L J Willmore, B J Wilder, J Bruni, H J Villarreal.   

Abstract

Altered hepatic function tests occurred in four of 25 patients treated with valproic acid. An average dose reduction in three patients of 10 mg per kilogram per day resulted in reversion of serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) to normal. The drug was discontinued in one patient. Careful monitoring of hepatic function is required of patients being treated with valproic acid, but our experience suggests that dose reduction alone may be effective in preventing untoward hepatic side effects.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 358014     DOI: 10.1212/wnl.28.9.961

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  13 in total

1.  Hyperammonaemia and hepatotoxicity during chronic valproate therapy: enhancement by combination with other antiepileptic drugs.

Authors:  R N Ratnaike; G J Schapel; G Purdie; R H Rischbieth; S Hoffmann
Journal:  Br J Clin Pharmacol       Date:  1986-07       Impact factor: 4.335

2.  Neurology-epitomes of progress: valproate: newest anticonvulsant.

Authors:  R I Pfeffer
Journal:  West J Med       Date:  1980-02

Review 3.  Biochemical relationships between Reye's and Reye's-like metabolic and toxicological syndromes.

Authors:  J Osterloh; W Cunningham; A Dixon; D Combest
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Jul-Aug

4.  Effect of long-term treatment with sodium valproate on gonadotrophin and prolactin secretion in paediatric patients.

Authors:  A Masala; T Meloni; S Alagna; P P Rovasio; S Rassu; G Mele; V Franca
Journal:  Br J Clin Pharmacol       Date:  1981-12       Impact factor: 4.335

5.  Free level monitoring of antiepileptic drugs. Clinical usefulness and case studies.

Authors:  E Perucca
Journal:  Clin Pharmacokinet       Date:  1984-01       Impact factor: 6.447

6.  Recent advances in drug therapy for epilepsy.

Authors:  J Bruni
Journal:  Can Med Assoc J       Date:  1979-04-07       Impact factor: 8.262

Review 7.  Valproate-associated hepatotoxicity and its biochemical mechanisms.

Authors:  M J Eadie; W D Hooper; R G Dickinson
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Mar-Apr

8.  Comparison of the effectiveness of several formulations of sodium valproate: tablets, enteric-coated capsules, solutions and rectal capsules.

Authors:  D Battino; M Biraghi; C Cusi; A Nespolo; G Avanzini
Journal:  Ital J Neurol Sci       Date:  1982-10

9.  Lack of effect of valproate on paracetamol (acetaminophen) disposition in epileptic patients.

Authors:  I M Kapetanović; H J Kupferberg; W Theodore; R J Porter
Journal:  Br J Clin Pharmacol       Date:  1981-04       Impact factor: 4.335

Review 10.  Valproate hepatotoxicity syndrome: hypotheses of pathogenesis.

Authors:  J R Stephens; R H Levy
Journal:  Pharm Weekbl Sci       Date:  1992-06-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.